COMMITED TO CBD & PSILOCYBIN SCIENCE!

 

 

The Company is currently positioning itself to become a major player in the estimated 146.4 billion dollars medical CBD (cannabidiol) space as well as the promising psilocybin medical health sector. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies.

 

Wuhan General Group, Inc. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that researches, develops and commercializes a range of CBD-based products under the Dr. AnnaRx and Medspresso brands. In addition, its new established division, M2Bio is researching and developing indications for psilocybin new therapies that will help patients who suffer from mental illness, Alzheimer’s and Parkinson’s. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies. Wuhan will enter the international growing cannabis and psilocybin market for medical applications such as cancer, mental disorders, chronic pain, and others is expected to propel revenue growth in Canada, the United States, South Africa and Europe.

 

From Seed to Store, a new efficient way to operate a company; from the cultivation, the processing, the manufacturing, the labeling, to the distribution in store – a chain of operation that enables us to maximize our profit, but also to be very competitive, and therefore guarantee an excellent product and service to our consumers.

WELCOME TO WUHAN GENERAL GROUP

About Our Company

Through its divisions, WGG is focusing in the psychedelics and in the medical cannabidiol (CBD) sectors. Wuhan enters the international 146.4 billion, and growing, cannabis market for medical applications such as cancer, mental disorders, chronic pain, and others, which are expected to propel revenue growth across Canada, South Africa, and Europe.

READ MORE ABOUT OUR COMPANY

People

Being an employer of choice and developing the leadership and organizational capacity within our talent pool to deliver on our long-term strategies.

Growth and performance

Sustaining or exceeding our historical revenue and organic growth performance, supplemented by acquisitions, while achieving strong margins.

Clients

Building a strong brand presence with our target audiences, and acting as their technology provider of choice by delivering an integrative, innovative client experience.

Shareholder value

Aligning our capital structure and investments to keep the business strong, while offering distribution of dividends.